MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2024 International Congress

    Comparison of olfactory testing and PSG for detection of alpha-synuclein pathology in patients with dream enactment behavior or REM sleep behavior disorder

    E. Brown, L. Chahine, A. Siderowf, C. Gochanour, C. Caspell-Garcia, M. Brumm, M. Marshall, C. Stanley, C. Soto, L. Concha, T. Sherer, T. Tanner, T. Simuni, K. Marek (San Francisco, USA)

    Objective: To compare the proportion of people with abnormal alpha-synuclein among groups with differing levels of certainty of REM sleep behavior disorder (RBD). Background: REM…
  • 2024 International Congress

    Pimavanserin Safety in Adult and Elderly Patients With Neuropsychiatric Symptoms Related to Neurodegenerative Disease: an Open-Label Extension Study

    W. Cubała, A. Berrio, K. Chi-Burris, G. Alva, L. Chrones, S. Pathak (Gdańsk, Poland)

    Objective: To assess the long-term safety and tolerability of pimavanserin in frail older adults and elderly patients with neuropsychiatric symptoms related to a neurodegenerative disease…
  • 2024 International Congress

    Identification of Allosteric GCase Correctors Using Revenir™ for the Treatment of GBA1-Parkinson’s Disease

    J. Dupaul-Chicoine, S. Lavallée, N. Azevedo Portilho, L. Gong, M. Fournel, I. Ghosh, MR. Goldsmith, M. Ebert, O. Rousseau, L. Fader, JF. Marquis, S. Hedge (Saint-Laurent, Canada)

    Objective: To identify novel non-inhibitory allosteric correctors of GCase using Congruence Therapeutic’s in silico proprietary drug discovery engine, Revenir™ Background: GBA1 encoding for glucocerebrosidase (GCase)…
  • 2024 International Congress

    Comparing Pramipexole and Ropinirole in the management of the tremor in Parkinson’s disease in the low-income country and environment of restricted medications.

    B. Mukhammedaminov (Uzbekistan, Uzbekistan)

    Objective: To inform the world community about the state situation on Parkinson’s disease in Uzbekistan. Objective: To Co inform the world community about the state…
  • 2024 International Congress

    Comparing the Selected Device-Aided Therapy of Movement Disorder Specialist Team with Patient Selections

    A. de Leon, O. Phokeawvarangkul, R. Bhidayasiri (Bangkok, Thailand)

    Objective: This study aims to compare the decision made by patients and physicians in selecting device-aided therapy (DAT) for advanced Parkinson’s disease (aPD) and to…
  • 2024 International Congress

    Combining Carbidopa/levodopa Extended-release Capsules and Immediate-release Tablets – Crucial Factors of This Economical Prescription

    Y. Tai, S. Hsu, H. Kuo (Kaohsiung City, Taiwan)

    Objective: We introduced a new way of prescribing carbidopa/levodopa extended-release (ER) capsule – combining use of immediate-release (IR) tablets. This retrospective clinical study was designed…
  • 2024 International Congress

    Effectiveness of Subthalamic nucleus (STN) Deep Brain Stimulation Surgery (DBS) in patients with Parkinson’s Disease: A Patient and Caregiver reported outcome

    S. Majumdar, S. Shee, S. Choudhury, J. Ganguly, P. Basu, N. Pandita, H. Kumar (Kolkata, India)

    Objective: We aim to assess the subjective impression on effectiveness and safety of Subthalamic nucleus Deep Brain Stimulation Surgery (STN-DBS) in patients with Parkinson’s Disease…
  • 2024 International Congress

    The Protective Role of Lysosomal Damage Response in Preventing α-Synuclein Propagation

    K. Kakuda, K. Ikenaka, C. Aguirre, C. Choong, Y. Kimura, J. Doi, H. Mochizuki (Suita, Japan)

    Objective: The aim of this study was to investigate the mechanism by which the lysosomal damage response (LDR) defends against the escape of α-synuclein (αSyn)…
  • 2024 International Congress

    Measures of Mitochondrial Function in Serum across the Parkinson’s Disease Spectrum

    L. Neilson, J. Elliott, M. Lim, N. Gray (Portland, USA)

    Objective: To resolve the inconsistencies in the magnitude and type of mitochondrial dysfunction within peripheral blood mononuclear cells (PBMCs) from people with Parkinson’s disease (PD),…
  • 2024 International Congress

    Association of Retinol Binding Protein (RBP) and the Risk of Parkinson’s disease (PD): A Narrative Literature Review

    V. Sharma (Urban, India)

    Objective: This review aimed to investigate the association between RBP levels and the risk of Parkinson’s disease Background: RBP facilitates retinol transport from the liver…
  • « Previous Page
  • 1
  • …
  • 60
  • 61
  • 62
  • 63
  • 64
  • …
  • 338
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Survey-Based study of marijuana used in Parkinson’s Disease patients
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley